PTC Historical Cash Flow

PTCT Stock

USD 43.88 1.23 2.73%

Analysis of PTC Therapeutics cash flow over time is an excellent tool to project PTC Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Cash of 330.1 M or Stock Based Compensation of 137.8 M as it is a great indicator of PTC Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining PTC Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether PTC Therapeutics is a good buy for the upcoming year.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.

About PTC Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in PTC balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which PTC's non-liquid assets can be easily converted into cash.

PTC Therapeutics Cash Flow Chart

At this time, PTC Therapeutics' Depreciation is comparatively stable compared to the past year. Other Non Cash Items is likely to gain to about 158.9 M in 2024, whereas Change In Working Capital is likely to drop (4.2 M) in 2024.

Capital Expenditures End Period Cash Flow Stock Based Compensation Begin Period Cash Flow

Capital Expenditures

Capital Expenditures are funds used by PTC Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of PTC Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most accounts from PTC Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into PTC Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.At this time, PTC Therapeutics' Depreciation is comparatively stable compared to the past year. Other Non Cash Items is likely to gain to about 158.9 M in 2024, whereas Change In Working Capital is likely to drop (4.2 M) in 2024.

	2021	2022	2023	2024 (projected)
Other Non Cash Items	128.3M	82.8M	151.3M	158.9M
Depreciation	64.1M	128.8M	236.6M	248.4M

Other Non Cash Items Depreciation

PTC Therapeutics cash flow statement Correlations

	Capital Expenditures	Change To Liabilities	End Period Cash Flow	Change In Cash	Stock Based Compensation	Free Cash Flow	Change In Working Capital	Begin Period Cash Flow	Depreciation	Other Non Cash Items	Change To Account Receivables	Net Income	Sale Purchase Of Stock	Change To Inventory	Investments	Change Receivables	Net Borrowings	Cash And Cash Equivalents Changes	Cash Flows Other Operating	Change To Netincome	Exchange Rate Changes	Change To Operating Activities	Issuance Of Capital Stock
Capital Expenditures		0.41	0.85	0.65	0.95	-0.92	-0.22	0.86	0.89	0.9	-0.43	-0.94	-0.25	-0.53	0.36	-0.81	0.3	0.51	0.01	0.71	-0.26	-0.97	-0.53
Change To Liabilities	0.41		0.45	0.12	0.51	-0.43	0.57	0.69	0.34	0.44	-0.37	-0.57	-0.19	-0.24	-0.11	-0.37	0.34	0.02	0.48	0.55	-0.1	-0.26	-0.15
End Period Cash Flow	0.85	0.45		0.89	0.9	-0.63	0.13	0.88	0.96	0.91	-0.05	-0.85	-0.16	-0.69	0.06	-0.67	0.44	0.65	-0.15	0.55	-0.2	-0.86	-0.4
Change In Cash	0.65	0.12	0.89		0.68	-0.35	0.04	0.57	0.84	0.74	0.15	-0.59	-0.04	-0.83	0.12	-0.51	0.49	0.85	-0.55	0.29	-0.07	-0.74	-0.22
Stock Based Compensation	0.95	0.51	0.9	0.68		-0.86	0.0	0.91	0.92	0.95	-0.41	-0.98	-0.43	-0.52	0.34	-0.86	0.28	0.43	0.11	0.76	-0.22	-0.9	-0.62
Free Cash Flow	-0.92	-0.43	-0.63	-0.35	-0.86		0.26	-0.76	-0.69	-0.75	0.61	0.9	0.34	0.27	-0.44	0.76	-0.21	-0.25	-0.2	-0.75	0.31	0.85	0.52
Change In Working Capital	-0.22	0.57	0.13	0.04	0.0	0.26		0.19	-0.01	0.0	0.3	-0.04	0.02	-0.05	-0.56	0.22	0.19	-0.12	0.24	-0.04	0.07	0.28	0.18
Begin Period Cash Flow	0.86	0.69	0.88	0.57	0.91	-0.76	0.19		0.87	0.87	-0.25	-0.93	-0.24	-0.38	-0.01	-0.67	0.29	0.28	0.29	0.69	-0.29	-0.78	-0.5
Depreciation	0.89	0.34	0.96	0.84	0.92	-0.69	-0.01	0.87		0.91	-0.12	-0.87	-0.27	-0.63	0.14	-0.74	0.26	0.53	-0.07	0.51	-0.18	-0.92	-0.6
Other Non Cash Items	0.9	0.44	0.91	0.74	0.95	-0.75	0.0	0.87	0.91		-0.29	-0.93	-0.26	-0.48	0.26	-0.8	0.26	0.48	0.07	0.79	-0.26	-0.85	-0.58
Change To Account Receivables	-0.43	-0.37	-0.05	0.15	-0.41	0.61	0.3	-0.25	-0.12	-0.29		0.42	0.56	0.07	-0.78	0.71	-0.08	0.08	-0.37	-0.59	0.18	0.31	0.46
Net Income	-0.94	-0.57	-0.85	-0.59	-0.98	0.9	-0.04	-0.93	-0.87	-0.93	0.42		0.37	0.42	-0.26	0.81	-0.28	-0.35	-0.2	-0.79	0.28	0.88	0.59
Sale Purchase Of Stock	-0.25	-0.19	-0.16	-0.04	-0.43	0.34	0.02	-0.24	-0.27	-0.26	0.56	0.37		0.13	-0.58	0.61	0.14	0.18	-0.29	-0.31	-0.21	0.24	0.65
Change To Inventory	-0.53	-0.24	-0.69	-0.83	-0.52	0.27	-0.05	-0.38	-0.63	-0.48	0.07	0.42	0.13		-0.28	0.5	-0.59	-0.85	0.59	-0.15	-0.14	0.61	0.11
Investments	0.36	-0.11	0.06	0.12	0.34	-0.44	-0.56	-0.01	0.14	0.26	-0.78	-0.26	-0.58	-0.28		-0.67	0.08	0.26	-0.16	0.44	0.07	-0.35	-0.36
Change Receivables	-0.81	-0.37	-0.67	-0.51	-0.86	0.76	0.22	-0.67	-0.74	-0.8	0.71	0.81	0.61	0.5	-0.67		-0.22	-0.33	-0.12	-0.71	0.23	0.77	0.76
Net Borrowings	0.3	0.34	0.44	0.49	0.28	-0.21	0.19	0.29	0.26	0.26	-0.08	-0.28	0.14	-0.59	0.08	-0.22		0.67	-0.47	0.26	-0.43	-0.28	0.35
Cash And Cash Equivalents Changes	0.51	0.02	0.65	0.85	0.43	-0.25	-0.12	0.28	0.53	0.48	0.08	-0.35	0.18	-0.85	0.26	-0.33	0.67		-0.79	0.22	-0.01	-0.58	0.18
Cash Flows Other Operating	0.01	0.48	-0.15	-0.55	0.11	-0.2	0.24	0.29	-0.07	0.07	-0.37	-0.2	-0.29	0.59	-0.16	-0.12	-0.47	-0.79		0.32	-0.11	0.14	-0.45
Change To Netincome	0.71	0.55	0.55	0.29	0.76	-0.75	-0.04	0.69	0.51	0.79	-0.59	-0.79	-0.31	-0.15	0.44	-0.71	0.26	0.22	0.32		-0.25	-0.57	-0.38
Exchange Rate Changes	-0.26	-0.1	-0.2	-0.07	-0.22	0.31	0.07	-0.29	-0.18	-0.26	0.18	0.28	-0.21	-0.14	0.07	0.23	-0.43	-0.01	-0.11	-0.25		0.2	0.08
Change To Operating Activities	-0.97	-0.26	-0.86	-0.74	-0.9	0.85	0.28	-0.78	-0.92	-0.85	0.31	0.88	0.24	0.61	-0.35	0.77	-0.28	-0.58	0.14	-0.57	0.2		0.54
Issuance Of Capital Stock	-0.53	-0.15	-0.4	-0.22	-0.62	0.52	0.18	-0.5	-0.6	-0.58	0.46	0.59	0.65	0.11	-0.36	0.76	0.35	0.18	-0.45	-0.38	0.08	0.54

Click cells to compare fundamentals

PTC Therapeutics Account Relationship Matchups

PTC Therapeutics cash flow statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Capital Expenditures	45.4M	56.0M	85.3M	152.5M	120.6M	126.6M
Total Cash From Financing Activities	613.2M	668.7M	20.9M	168.0M	646.4M	678.7M
Change To Liabilities	40.5M	66.9M	41.6M	23.0M	26.4M	25.6M
End Period Cash Flow	295.5M	216.3M	197.2M	295.9M	610.3M	640.8M
Change In Cash	126.0M	(79.2M)	(19.1M)	98.7M	314.4M	330.1M
Stock Based Compensation	42.1M	70.3M	103.5M	110.3M	131.2M	137.8M
Free Cash Flow	(144.1M)	(250.0M)	(336.7M)	(509.1M)	(279.0M)	(265.1M)
Change In Working Capital	20.4M	36.9M	(23.8M)	(85.3M)	(4.0M)	(4.2M)
Begin Period Cash Flow	169.5M	295.5M	216.3M	197.2M	295.9M	310.7M
Total Cashflows From Investing Activities	(387.2M)	(561.5M)	219.2M	290.2M	333.7M	350.4M
Other Cashflows From Financing Activities	301.1M	686.8M	23.1M	(30.8M)	947.8M	995.2M
Depreciation	32.2M	84.9M	64.1M	128.8M	236.6M	248.4M
Other Non Cash Items	49.4M	46.1M	128.3M	82.8M	151.3M	158.9M
Total Cash From Operating Activities	(98.6M)	(194.1M)	(251.3M)	(356.7M)	(158.4M)	(166.3M)
Change To Account Receivables	11.5M	(10.5M)	(45.0M)	(48.5M)	(1.5M)	(1.6M)
Net Income	(251.6M)	(438.2M)	(523.9M)	(559.0M)	(626.6M)	(595.3M)
Sale Purchase Of Stock	345.6M	103.6M	23.1M	71.1M	64.0M	89.2M
Change To Inventory	(3.5M)	1.8M	1.8M	(6.7M)	(8.2M)	(7.8M)
Investments	(341.8M)	(505.6M)	304.5M	442.6M	(49.9M)	(47.4M)
Change Receivables	11.5M	(10.5M)	(45.0M)	(48.5M)	(43.6M)	(41.4M)
Cash And Cash Equivalents Changes	126.0M	(86.9M)	(11.3M)	101.5M	116.7M	122.5M
Cash Flows Other Operating	(24.4M)	75.8M	54.7M	(11.7M)	(13.5M)	(12.8M)
Other Cashflows From Investing Activities	(31.7M)	(38.1M)	(57.1M)	(120.4M)	(108.4M)	(103.0M)
Change To Netincome	97.8M	65.1M	230.4M	113.8M	130.8M	79.0M
Change To Operating Activities	(13.1M)	(17.2M)	(22.2M)	(68.7M)	(61.8M)	(58.7M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for PTC Stock Analysis

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

PTC Historical Cash Flow

About PTC Cash Flow Analysis

PTC Therapeutics Cash Flow Chart

Capital Expenditures

Stock Based Compensation

Begin Period Cash Flow

PTC Therapeutics cash flow statement Correlations

PTC Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

PTC Therapeutics cash flow statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for PTC Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Depreciation	+ 0.96	End Period Cash Flow
Stock Based Compensation	+ 0.95	Capital Expenditures
Other Non Cash Items	+ 0.95	Stock Based Compensation
Depreciation	+ 0.92	Stock Based Compensation
Other Non Cash Items	+ 0.91	End Period Cash Flow
Begin Period Cash Flow	+ 0.91	Stock Based Compensation

Net Income	- 0.98	Stock Based Compensation
Change To Operating Activities	- 0.97	Capital Expenditures
Net Income	- 0.94	Capital Expenditures
Net Income	- 0.93	Other Non Cash Items
Net Income	- 0.93	Begin Period Cash Flow
Change To Operating Activities	- 0.92	Depreciation